Benini Franca, Barbi Egidio
Pediatric Pain and Palliative Care Service, Department of Maternal and Child Health, University of Padua, Padua, Italy.
Ital J Pediatr. 2014 Feb 11;40(1):16. doi: 10.1186/1824-7288-40-16.
Codeine is a mild opioid widely used as an analgesic in various age groups, including various pediatric settings. It is a prodrug that owes its analgesic effect almost entirely to the principal metabolite: morphine. The genetic polymorphisms can contribute to making the pharmacokinetics of codeine hard to predict and this it is particularly important in the pediatric population because infants and children have greater susceptibility to the side-effects of morphine. In recent years there have been several reports in the literature on the risks relating to the use of codeine. In August 2012, the American Food and Drugs Administration began to revise its recommendations for the safe use of codeine and in February 2013, established that codeine should not be used for postoperative pain control in children undergoing adenoidectomy and/or tonsillectomy and did restrict the use of this drug in the pediatric population. In June 2013, the European Medicine Agency opted the same decision. In July 2013, the Agenzia Italiana del Farmaco prohibit the use of medicines containing codeine for patients under 12 years old and recommended a limited use of the drug, in many other situations. Complying with these recommendations naturally means changing habits and treatment strategies well established in pediatric practice, but other drugs, tools and techniques available enable us to continue to assure an adequate pain control in pediatric patients, irrespective of their age and situation. The article proposes same alternatives of pain control drugs.
可待因是一种温和的阿片类药物,广泛用于各年龄组,包括各种儿科情况。它是一种前体药物,其镇痛作用几乎完全归因于主要代谢产物:吗啡。基因多态性会导致可待因的药代动力学难以预测,这在儿科人群中尤为重要,因为婴儿和儿童对吗啡的副作用更敏感。近年来,文献中有几篇关于使用可待因的风险的报告。2012年8月,美国食品药品监督管理局开始修订其关于可待因安全使用的建议,并于2013年2月规定,可待因不应用于接受腺样体切除术和/或扁桃体切除术的儿童的术后疼痛控制,并确实限制了该药物在儿科人群中的使用。2013年6月,欧洲药品管理局做出了同样的决定。2013年7月,意大利药品管理局禁止12岁以下患者使用含可待因的药物,并建议在许多其他情况下有限使用该药物。遵守这些建议自然意味着改变儿科实践中早已确立的习惯和治疗策略,但现有的其他药物、工具和技术使我们能够继续确保无论儿科患者的年龄和情况如何,都能获得充分的疼痛控制。本文提出了一些疼痛控制药物的替代方案。